Effective in skin types IV–VI where hydroquinone carries elevated risks.
First-choice brightener for Fitzpatrick IV–VI. Tolerable with retinoids and vitamin C in evening protocols. Pregnancy-safe (Category B).
If you're targeting melasma, this research supports adding azelaic acid to your AM/PM routine. Effective concentration range: 4% based on this study. Timeline to expect: 24 weeks based on study duration.
Translated from this study's findings, not a personal prescription. Pair with your existing protocol and your practitioner's guidance.
AzA 20% cream and 15% gel produce melasma improvement comparable to HQ 4% at 24 weeks across multiple trials. Mechanisms: competitive tyrosinase inhibition, mitochondrial enzyme interference, anti-keratinizing effect. Especially valuable in Fitzpatrick IV–VI where HQ-induced ochronosis is a concern.
Azelaic acid (AzA) is a dicarboxylic acid with tyrosinase-inhibiting, antioxidant, and anti-inflammatory activity. Multiple controlled trials demonstrate efficacy comparable to hydroquinone 4% in melasma at 24 weeks, with superior safety profile and no ochronosis risk. Effective in skin types IV–VI where hydroquinone carries elevated risks.
Original source →Skin dullness, characterized by pigmentation disorders and yellowing, is a major cosmetic concern in Asian populations. Lipofuscin exhibits ultraviolet (UV)/visible light spectral absorption, reduces skin reflectance, and contributes to dullness, whereas existing therapies targeting melanogenesis and glycation lack comprehensive efficacy. This study aimed to evaluate the multimodal anti-dullness effects of a novel formulation (HNHT: hyaluronic acid, niacinamide, hydrolyzed red algae, and tranexamic acid).
Melasma is a chronic, acquired facial hyperpigmentation disorder with multifactorial pathogenesis and frequent relapse. Low-fluence 1064-nm Q-switched neodymium-doped yttrium aluminum garnet (Nd:YAG) (LQSNY) laser with oral tranexamic acid (TA) is widely used, but responses are often incomplete and short-lived. glutathione (GSH), an antioxidant that inhibits melanogenesis, may improve outcomes when delivered intradermally with a hyaluronic acid (HA) carrier.
There is increasing interest in non-invasive options for chest rejuvenation with minimal to no downtime. Topical retinoids have long been used to correct photoaging due to their ability to promote epidermal hyperplasia, matrix metalloproteinase inhibition, collagen synthesis, and dispersion of melanin granules. Topical retinoid use is often limited by the ensuing irritation that occurs with initial use and resolves after about one month.
This information is for educational purposes only and is not medical advice. Individual results vary. Consult a qualified dermatologist or healthcare professional for medical concerns. Full disclaimer →